Foley & Lardner LLP partner Louis Lehot is quoted in the Law360 article, “Attys Hopeful For Deals Pickup As JPMorgan Event Kicks Off,” offering perspective ahead of the annual J.P. Morgan Healthcare Conference in San Francisco on capital-raising and mergers and acquisitions, in particular for the health care and life sciences sector.
“What a life sciences investor needs is a risk-on environment and a good portfolio of companies that have molecules that can go to market in the near term,” explained Lehot. “And that means they can be an acquisition target.”
(Subscription required)
People
Related News
October 9, 2026
In the News
Jonathan Lasken Highlighted Across the Media for Arrival to Foley
Foley & Lardner LLP partner Jonathan Lasken is highlighted across the media for his recent arrival to the firm’s Washington D.C. office.
October 7, 2026
In the News
William Holtz Examines New FDA Approach to Clinical Trial Development
Foley & Lardner LLP of counsel William Holtz is quoted in the PharmaVoice article, “5 Key Facts About the FDA Expedited IND Pilot Program,” examining the FDA's new pilot program and its potential to accelerate clinical research.
October 5, 2026
In the News
Louis Lehot Analyzes U.S. IPO Market Trends and Outlook
Foley & Lardner LLP partner Louis Lehot is featured in the Daily Journal‘s Capital & Counsel newsletter offering insights on the current state of the U.S. IPO market and the factors influencing companies' routes to going public.